Galimedix Therapeutics
PrivateLast Round
Strategic
Mar 29, 2023
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Galimedix Therapeutics operates in Healthcare & Life Sciences and is based in Kensington, Maryland. Its latest recorded funding round was a Strategic round in March 2023.
Galimedix Therapeutics is a clinical-stage biotechnology company that develops small molecule drugs for neurodegenerative diseases such as dry age-related macular degeneration (AMD), glaucoma, and Alzheimer's disease.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Galimedix Therapeutics Comparables
Compare Galimedix Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Broadwing Bio | 73% | |
| Telara Pharma | 71% | |
| AltRegen | 71% |
For institutional investors. Book with your work email.
Galimedix Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Mar 29, 2023 | ||||
| Seed | Jan 1, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Galimedix Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Théa Open Innovation | Strategic |
| Rimonci | Seed |
| InFocus Capital Partners | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors grew 206% MoM, reaching 2.5K.
- May 1, 2025
Monthly visitors increased 217% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventSep 11, 2026
Galimedix Therapeutics, Inc. presents data from its ongoing Phase 2 eDREAM study evaluating GAL-101 in geographic atrophy at the 26th EURETINA Congress on Oct 1st '26.
For institutional investors. Book with your work email.
Galimedix Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Galimedix Therapeutics's valuation, stock price, and market status.
Is Galimedix Therapeutics a public or private company?
Galimedix Therapeutics is a private company.
What is the current stock price of Galimedix Therapeutics?
Galimedix Therapeutics is a private company, so its shares have no public market price. Caplight tracks Galimedix Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Galimedix Therapeutics worth (valuation)?
Valuation information for Galimedix Therapeutics is not publicly available.
Can I buy Galimedix Therapeutics stock?
Galimedix Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Galimedix Therapeutics's last funding round?
Galimedix Therapeutics's most recent funding round was Strategic on March 29, 2023.
Who are the main investors in Galimedix Therapeutics?
Key investors in Galimedix Therapeutics include Théa Open Innovation.
Will Galimedix Therapeutics IPO soon?
No public IPO plans have been announced for Galimedix Therapeutics.
How can I track Galimedix Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Galimedix Therapeutics's shares on secondary markets.